MyMyelomaTeam

For standard-risk multiple myeloma, lenalidomide (Revlimid) is the current standard of care used in maintenance therapy. Studies have shown that lenalidomide can significantly improve progression-free survival and sustain remission after stem cell transplant for around 57 months compared to 30 months without maintenance Show Full Answer

For standard-risk multiple myeloma, lenalidomide (Revlimid) is the current standard of care used in maintenance therapy. Studies have shown that lenalidomide can significantly improve progression-free survival and sustain remission after stem cell transplant for around 57 months compared to 30 months without maintenance treatment.

However, it's important to discuss with your oncologist to tailor the treatment plan to your specific health needs, including your creatinine levels and any other individual factors.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Facts About Myeloma Maintenance Therapy | MyMyelomaTeam

New Treatment Options for Relapsed or Refractory Myeloma | MyMyelomaTeam